11 hours Gilead Science to Report Q3 Earnings: What’s in the Cards?Zacks
Investors’ focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
Biotech · Earnings · Gilead (GILD) · Science
X